These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide. Batchelor WB; Tolleson TR; Huang Y; Larsen RL; Mantell RM; Dillard P; Davidian M; Zhang D; Cantor WJ; Sketch MH; Ohman EM; Zidar JP; Gretler D; DiBattiste PM; Tcheng JE; Califf RM; Harrington RA Circulation; 2002 Sep; 106(12):1470-6. PubMed ID: 12234950 [TBL] [Abstract][Full Text] [Related]
3. Differences among the parenteral platelet glycoprotein IIb/IIIa inhibitors and implications for treatment. Tcheng JE Am J Cardiol; 1999 May; 83(9A):7E-11E. PubMed ID: 10357575 [No Abstract] [Full Text] [Related]
4. High platelet count in platelet-rich plasma reduces measured platelet inhibition by abciximab but not tirofiban nor eptifibatide glycoprotein IIb/IIIa receptor antagonists. Kereiakes DJ; Broderick TM; Roth EM; Whang D; Mueller M; Lacock P; Anderson LC; Howard W; Blanck C; Schneider J; Abbottsmith CA J Thromb Thrombolysis; 2000 Feb; 9(2):149-55. PubMed ID: 10613996 [TBL] [Abstract][Full Text] [Related]
6. Effects Of Glycoprotein IIb/IIIa Antagonists: Anti Platelet Aggregation And Beyond. Giordano A; Musumeci G; D'Angelillo A; Rossini R; Zoccai GB; Messina S; Coscioni E; Romano S; Romano MF Curr Drug Metab; 2016; 17(2):194-203. PubMed ID: 26652157 [TBL] [Abstract][Full Text] [Related]
7. Abciximab, eptifibatide, and tirofiban exhibit dose-dependent potencies to dissolve platelet aggregates. Moser M; Bertram U; Peter K; Bode C; Ruef J J Cardiovasc Pharmacol; 2003 Apr; 41(4):586-92. PubMed ID: 12658060 [TBL] [Abstract][Full Text] [Related]
8. Effect of Ca2+ chelation on the platelet inhibitory ability of the GPIIb/IIIa antagonists abciximab, eptifibatide and tirofiban. Marciniak SJ; Jordan RE; Mascelli MA Thromb Haemost; 2001 Mar; 85(3):539-43. PubMed ID: 11307828 [TBL] [Abstract][Full Text] [Related]
9. Current issues with glycoprotein IIb-IIIa antagonists. Schneider DJ Curr Drug Targets; 2011 Nov; 12(12):1813-20. PubMed ID: 21718238 [TBL] [Abstract][Full Text] [Related]
10. IIb's are not IIb's. Kereiakes DJ; Runyon JP; Broderick TM; Shimshak TM Am J Cardiol; 2000 Apr; 85(8A):23C-31C. PubMed ID: 10793177 [TBL] [Abstract][Full Text] [Related]
11. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation. Nannizzi-Alaimo L; Alves VL; Phillips DR Circulation; 2003 Mar; 107(8):1123-8. PubMed ID: 12615789 [TBL] [Abstract][Full Text] [Related]
12. Different effects of various anti-GPIIb-IIIa agents on shear-induced platelet activation and expression of procoagulant activity. Goto S; Tamura N; Li M; Handa M; Ikeda Y; Handa S; Ruggeri ZM J Thromb Haemost; 2003 Sep; 1(9):2022-30. PubMed ID: 12941046 [TBL] [Abstract][Full Text] [Related]
13. Abciximab pharmacodynamics are unaffected by antecedent therapy with other GPIIb/IIIa antagonists in non-human primates. Nakada MT; Sassoli PM; Tam SH; Nedelman MA; Jordan RE; Kereiakes DJ J Thromb Thrombolysis; 2002 Aug; 14(1):15-24. PubMed ID: 12652146 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of platelet-dependent prothrombinase activity and thrombin generation by glycoprotein IIb/IIIa receptor-directed antagonists: potential contributing mechanism of benefit in acute coronary syndromes. Li Y; Spencer FA; Ball S; Becker RC J Thromb Thrombolysis; 2000 Aug; 10(1):69-76. PubMed ID: 10947916 [TBL] [Abstract][Full Text] [Related]
15. Abciximab, eptifibatide, and tirofiban: comparison of parenteral glycoprotein IIb/IIIa inhibitors. Dunn A Conn Med; 1999 Aug; 63(8):483-7. PubMed ID: 10500344 [No Abstract] [Full Text] [Related]
16. [Pathophysiology of platelet activation and pharmacology of GPIIb/IIIa inhibitors]. Schrör K Herz; 2001 Apr; 26 Suppl 1():30-5. PubMed ID: 11349624 [TBL] [Abstract][Full Text] [Related]
17. Differential inhibitory effects of platelet glycoprotein IIb/IIIa antagonists on aggregation induced by procoagulant agonists. Ilveskero S; Lassila R Thromb Res; 2006; 117(3):291-7. PubMed ID: 15878612 [TBL] [Abstract][Full Text] [Related]